Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study Repurposing ATRA as Stromal Targeting Agent Along With Gemcitabine and Nab-Paclitaxel for Pancreatic Cancer (STAR_PAC)

NCT03307148 is registered in ClinicalTrials.gov with Barts & The London NHS Trust as lead sponsor.

NCT NCT03307148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03307148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study Repurposing ATRA as Stromal Targeting Agent Along With Gemcitabine and Nab-Paclitaxel for Pancreatic Cancer (STAR_PAC)
Lead sponsor
Barts & The London NHS Trust
Phase
Phase 1
Overall status
Completed
Start date
January 15, 2016
Completion date
March 19, 2019
Enrollment
29 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma